The prometastatic relevance of tumor‐infiltrating B lymphocytes in laryngeal squamous cell carcinoma

Laryngeal squamous cell carcinomas (LSCCs) typically have an excellent prognosis for stage I tumors but a significant risk of locoregional and distant recurrence for intermediate to advanced disease. This study will investigate the clinical relevance of the tumor microenvironment in a large cohort of treatment‐naïve patients affected by stage II–IV LSCC.

[1]  K. To,et al.  TGF-β signaling networks in the tumor microenvironment. , 2022, Cancer letters.

[2]  R. Uppaluri,et al.  Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck Cancer , 2022, Current Otorhinolaryngology Reports.

[3]  Lei Zhang,et al.  CD8+ T-cell exhaustion in the tumor microenvironment of head and neck squamous cell carcinoma determines poor prognosis , 2021, Annals of translational medicine.

[4]  E. Di Carlo,et al.  Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival , 2021, Frontiers in Immunology.

[5]  A. Broeks,et al.  Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma , 2021, Nature Communications.

[6]  C. Ries,et al.  Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes , 2021, Frontiers in immunology.

[7]  G. Kinker,et al.  B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication , 2021, Frontiers in Cell and Developmental Biology.

[8]  J. Aguillón,et al.  Immunosuppressive Mechanisms of Regulatory B Cells , 2021, Frontiers in Immunology.

[9]  Michelle D. Williams,et al.  Tumor-Infiltrating Lymphocytes in the Tumor Microenvironment of Laryngeal Squamous Cell Carcinoma: Systematic Review and Meta-Analysis † , 2021, Biomedicines.

[10]  Jiang Ren,et al.  Targeting TGFβ signal transduction for cancer therapy , 2021, Signal Transduction and Targeted Therapy.

[11]  A. Egloff,et al.  Tumor‐associated neutrophils (TANs) in human carcinoma‐draining lymph nodes: a novel TAN compartment , 2021, Clinical & translational immunology.

[12]  M. Spampinato,et al.  Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma , 2019, Cell reports. Medicine.

[13]  S. Salas,et al.  Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies , 2020, Journal for ImmunoTherapy of Cancer.

[14]  Christopher C. Griffith,et al.  Defining HPV-specific B cell responses in patients with head and neck cancer , 2020, Nature.

[15]  Liang Zhou,et al.  Prognostic Impact of Tumor‐Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma Patients , 2020, The Laryngoscope.

[16]  R. Tishler,et al.  Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. , 2020, JAMA oncology.

[17]  J. Tabernero,et al.  Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Ravaud,et al.  Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort , 2020, Journal for ImmunoTherapy of Cancer.

[19]  C. R. Leemans,et al.  The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: on Subsets and Subsites , 2020, Current Oncology Reports.

[20]  S. Marceglia,et al.  Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma , 2020, Cancers.

[21]  D. Schadendorf,et al.  Tertiary lymphoid structures improve immunotherapy and survival in melanoma , 2020, Nature.

[22]  A. Psyrri,et al.  Tumor Infiltrating Lymphocytes and CD8+ T Cell Subsets as Prognostic Markers in Patients with Surgically Treated Laryngeal Squamous Cell Carcinoma , 2019, Head and Neck Pathology.

[23]  B. Monk,et al.  Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State , 2019, Targeted Oncology.

[24]  R. Hart,et al.  Systematic review and meta-analysis of T1 glottic cancer outcomes comparing CO2 transoral laser microsurgery and radiotherapy , 2019, Journal of Otolaryngology - Head & Neck Surgery.

[25]  Yanqiu Zhang,et al.  Circulating exosomes from esophageal squamous cell carcinoma mediate the generation of B10 and PD‐1high Breg cells , 2019, Cancer science.

[26]  Guodong Li,et al.  Assessment of tumor-associated immune cells in laryngeal squamous cell carcinoma , 2019, Journal of Cancer Research and Clinical Oncology.

[27]  Eduard Batlle,et al.  Transforming Growth Factor-β Signaling in Immunity and Cancer. , 2019, Immunity.

[28]  A. Ghaderi,et al.  The significance of cytokine-producing B cells in breast tumor-draining lymph nodes , 2019, Cellular Oncology.

[29]  Francis Deng,et al.  WHO classification of head and neck tumors , 2019, Radiopaedia.org.

[30]  O. V. Matorin,et al.  Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study , 2019, The Lancet.

[31]  K. Malloy,et al.  Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma , 2018, Cancer Immunology, Immunotherapy.

[32]  T. Seiwert,et al.  Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 , 2018, British Journal of Cancer.

[33]  Si-Si Wang,et al.  Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer , 2018, Cellular & Molecular Immunology.

[34]  C. Bradford,et al.  Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. , 2018, Oral oncology.

[35]  A. Bankfalvi,et al.  Stromal versus tumoral inflammation differentially contribute to metastasis and poor survival in laryngeal squamous cell carcinoma , 2017, Oncotarget.

[36]  Wei Liu,et al.  Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer , 2018, Cellular & Molecular Immunology.

[37]  M. Mareel,et al.  Distant metastases in head and neck cancer , 2017, Head & neck.

[38]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[39]  P. Validire,et al.  Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma , 2017, Clinical Cancer Research.

[40]  P. Fournel,et al.  Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics , 2016, Oncotarget.

[41]  J. Radford.  Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.

[42]  A. Hakimi,et al.  The head and neck cancer immune landscape and its immunotherapeutic implications. , 2016, JCI insight.

[43]  J. Zucman‐Rossi,et al.  Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC) , 2015, Oncoimmunology.

[44]  Antoni Ribas,et al.  Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.

[45]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[46]  Enlong Ma,et al.  Glioma cell-derived placental growth factor induces regulatory B cells. , 2014, The international journal of biochemistry & cell biology.

[47]  Deepak Mittal,et al.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.

[48]  J. Berzofsky,et al.  Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma , 2014, PloS one.

[49]  A. Biragyn,et al.  Generation and identification of tumor-evoked regulatory B cells. , 2014, Methods in molecular biology.

[50]  V. Gaetano,et al.  Regulatory B Cells , 2014, Methods in Molecular Biology.

[51]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[52]  M. Merino,et al.  Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. , 2013, Cancer research.

[53]  C. Mauri,et al.  Immune regulatory function of B cells. , 2012, Annual review of immunology.

[54]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[55]  M. Shlomchik,et al.  B Cell-Derived IL-10 Does Not Regulate Spontaneous Systemic Autoimmunity in MRL.Faslpr Mice , 2012, The Journal of Immunology.

[56]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[57]  N. Rekhtman,et al.  Quick Reference Handbook for Surgical Pathologists , 2011 .

[58]  Xiao-yan Li,et al.  Chinese Anti鄄 Cancer a Ssociation , 2022 .

[59]  T. Tedder,et al.  B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer , 2010, Annals of the New York Academy of Sciences.

[60]  T. Tsubata,et al.  The Development and Function of Regulatory B Cells Expressing IL-10 (B10 Cells) Requires Antigen Receptor Diversity and TLR Signals1 , 2009, The Journal of Immunology.

[61]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[62]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .

[63]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[64]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[65]  R. Weber,et al.  Laryngeal Cancer in the United States: Changes in Demographics, Patterns of Care, and Survival , 2006, The Laryngoscope.

[66]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[67]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[68]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[69]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[70]  F. Preffer,et al.  Suppressive Role of B Cells in Chronic Colitis of  T Cell Receptor α Mutant Mice , 1997, The Journal of experimental medicine.

[71]  F. Preffer,et al.  Suppressive Role of B Cells in Chronic Colitis of T Cell Receptor (cid:97) Mutant Mice , 1997 .

[72]  J. Cooper.  Ajcc Cancer Staging Manual , 1997 .

[73]  Charles A. Janeway,et al.  Experimental Autoimmune Encephalomyelitis Induction in Genetically B Cell–deficient Mice , 1996, The Journal of experimental medicine.

[74]  Peter J. Rousseeuw,et al.  Finding Groups in Data: An Introduction to Cluster Analysis , 1990 .